| 2 months | 4 months | 9 months |
---|
 |
control
|
control
|
PIO
|
IBU
|
control
|
 |
T-
|
T+
|
T-
|
T+
|
T-
|
T+
|
T-
|
T+
|
T-
|
T+
|
Aβ40
| 9.8 ± 1.7 | 10.1 ± 1.1 | 9.5 ± 2.5 | 9.6 ± 2.1 | 8.5 ± 2.2 | 8.3 ± 1.5 | 9.9 ± 0.9 | 10.5 ± 2.0 | 9.2 | 18.6 |
Aβ42
| 7.2 ± 1.5 | 7.2 ± 1.0 | 6.8 ± 2.7 | 6.9 ± 1.7 | 5.2 ± 1.5* | 4.7 ± 0.7* | 7.2 ± 1.3 | 7.2 ± 1.8 | 6.5 | 7.8 |
ratio 42/40
| 0.74 | 0.71 | 0.71 | 0.73 | 0.61 | 0.57 | 0.73 | 0.68 | 0.71 | 0.42 |
n
| 6 | 4 | 8 | 8 | 6 | 5 | 6 | 7 | 4 | 5 |
- Values are means in fmol / mg protein ± SD, except at 9 months where measurements were performed in pooled hippocampi. Results: i) no difference between T+ and T- groups at 2 or 4 months; ii) increase in Aβ40 in T+ at 9 months; iii) decrease of basal Aβ42 but not Aβ40 by pioglitazone in T- and T+ groups (*) p = 0.013, PIO versus control, two-way ANOVA analysis; iv) no effect of Ibuprofen. n, number of animals, T-, non transgenic mice; T+, TGF-β1 mice.